Size: | Price | Quantity | |
---|---|---|---|
5 mg | $60.00 | ||
25 mg | $225.00 |
NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM).1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.3
References/Citations:
1) Mautino et al. (2013), NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy; Cancer Res. 73 issue 8 supplement 491
2) Li et al. (2014), The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma; J. Immunother. Cancer 2 21
3) Meng et al. (2017), Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model; Int. J. Immunopathol. Pharmacol. 30 215
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM).1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.3
References/Citations:
1) Mautino et al. (2013), NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy; Cancer Res. 73 issue 8 supplement 491
2) Li et al. (2014), The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma; J. Immunother. Cancer 2 21
3) Meng et al. (2017), Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model; Int. J. Immunopathol. Pharmacol. 30 215
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.